RESUMEN
In a double-blind crossover study, it has been shown that the hypotensive response to propranolol in 24 patients with essential hypertension was no greater at doses of 80, 160, or 240 mg twice daily than at 40 mg twice daily. A relationship was observed between dose and response as defined by the ability to achieve a standing diastolic blood pressure of 95 mm Hg. Four patients with low plasma renin activity (PRA) had no fall in blood pressure even at highest dose levels. Plasma propranolol levels in the groups were related to dose, and up to a concentration of 300 ng/ml, with degree of beta-adrenoceptor blockade; there was, however, no correlation with hypotensive response.
Asunto(s)
Hipertensión/tratamiento farmacológico , Propranolol/uso terapéutico , Antagonistas Adrenérgicos beta/farmacología , Adulto , Presión Sanguínea/efectos de los fármacos , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Postura , Propranolol/administración & dosificación , Propranolol/sangre , Pulso Arterial/efectos de los fármacos , Renina/sangreRESUMEN
The effect of diflunisal on steady-state warfarin dynamics and kinetics was studied in five healthy men taking daily subtherapeutic doses of warfarin. Diflunisal 500 mg twice daily for 2 wk increased the percentage unbound warfarin from 1.02% to 1.24% and lowered total warfarin from 741 to 533 ng/ml, but did not alter the anticoagulant response (prothrombin complex activity, PCA). When diflunisal was discontinued but warfarin continued, there was a loss of anticoagulant effect and a difference in the rates at which percentage unbound warfarin and total warfarin concentration returned to prediflunisal levels. There was a correlation between plasma diflunisal and percentage unbound warfarin. Diflunisal reduced both the maximum plasma protein-binding capacity for warfarin and the apparent association constant.
Asunto(s)
Diflunisal/farmacología , Salicilatos/farmacología , Warfarina/metabolismo , Absorción , Adulto , Proteínas Sanguíneas/metabolismo , Diflunisal/metabolismo , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Humanos , Masculino , Unión Proteica , Protrombina/análisisRESUMEN
The influence of urinary pH on the plasma levels and renal elimination of unchanged indomethacin has been studied in seven healthy volunteers with the use of a specific and sensitive gas-liquid chromatographic method assay for indomethacin in plasma and urine. There is a wide variation in the terminal t1/2 (2.5-10.3 h) and the AUC (5264-12693 ng/ml h) of indomethacin after a standard oral dose (50 mg) under 'normal' urinary condition. Such variation is probably, in part, due to an intersubject difference in extrarenal elimination of the drug. The urinary recovery of unchanged indomethacin is highest at alkaline pH (15.7 +/- 5.3%), lowest at acidic pH (3.5 +/- 2.0%) and the 'normal' value is 7.1 +/- 1.6%. These differences are statistically significant. Despite such influence there is no apparent change in plasma levels of the drug under uncontrolled and controlled (acidic and alkaline) conditions of urinary pH. The clinical implication is that possible changes in urinary pH during long-term treatment of arthritic patients may not affect the overall kinetics of indomethacin which is extensively eliminated by the extrarenal route.
Asunto(s)
Indometacina/orina , Absorción , Mejilla , Semivida , Humanos , Concentración de Iones de Hidrógeno , Indometacina/sangre , Masculino , Mucosa Bucal/metabolismo , Factores de Tiempo , Orina/análisisRESUMEN
1 In five volunteers taking daily subtherapeutic doses of warfarin the addition of ranitidine 200 mg twice daily for 14 days did not affect prothrombin time or plasma warfarin concentration. 2 Ranitidine had no effect on the single dose pharmacodynamics and pharmacokinetics of warfarin in the rat. 3 Ranitidine had no effect on pentobarbitone sleeping time in the rat whereas cimetidine significantly prolonged the sleeping time. 4 The interaction between cimetidine and oral anticoagulants is unrelated to histamine H2-receptor antagonism.
Asunto(s)
Furanos/farmacología , Antagonistas de los Receptores H2 de la Histamina/farmacología , Warfarina/farmacología , Adulto , Animales , Interacciones Farmacológicas , Semivida , Humanos , Cinética , Masculino , Pentobarbital/farmacología , Tiempo de Protrombina , Ranitidina , Ratas , Ratas Endogámicas , Sueño/efectos de los fármacos , Factores de Tiempo , Warfarina/sangreRESUMEN
A sensitive and specific gas chromatographic method for the analysis of indomethacin has been developed. After extraction of the drug from blood or urine with ethylene dichrloride a derivative is formed with pentafluorobenzyl bromide. 5-Fluoro-indomethacin is used as an internal standard. The overall recovery of indomethacin is 85.1 +/- 2.3% and the method can detect 10 ng indomethacin in a 1 ml plasma or urine sample. No interference in the method is seen with some commonly used drugs. The method has been used to measure plasma indomethacin concentrations in 20 patients with rheumatoid arthritis, being treated with 25 mg indomethacin three times daily. The plasma concentration ranged from 168-596 ng/ml.
Asunto(s)
Indometacina/sangre , Animales , Cromatografía de Gases/métodos , Cromatografía Liquida/métodos , Indometacina/orinaRESUMEN
Twenty-one patients with rheumatoid arthritis were given indomethacin 25 mg t.i.d. by mouth for 3 weeks followed by indomethacin 25 mg t.i.d. plus a 100 mg suppository at night, after a 5-day period on placebo capsules. The mean (+/- S.E.) 24-hour creatinine clearance was 57.8 +/- 5.7 ml/min in the placebo period and was not significantly altered during indomethacin therapy, 53.1 +/- 5.5 ml/min in the oral period and 56.6 +/- 6.4 ml/min in the oral plus suppository period (P greater than 0.1). In 6 volunteers, duplicate 2-hour creatinine clearances were performed after a single oral dose of 50 mg indomethacin. After placebo capsules the mean creatinine clearance was 133.7 +/- 9.5 ml/min and after 50 mg indomethacin it was 126.5 +/- 8.9 ml/min (P greater than 0.1). In 4 of the volunteers the mean creatinine clearance after 8 days on indomethacin 25 mg q.i.d. was 117.1+/- 5.3 ml/min (P greater than 0.1). Indomethacin plasma concentrations were in the usual range for the dose given. Indomethacin caused no reduction in the creatinine clearance in spite of causing significant inhibition of prostaglandin E synthesis.
Asunto(s)
Indometacina/efectos adversos , Riñón/efectos de los fármacos , Administración Oral , Adolescente , Adulto , Anciano , Creatinina/sangre , Creatinina/orina , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Indometacina/administración & dosificación , Masculino , Persona de Mediana Edad , Placebos , Supositorios , Factores de TiempoRESUMEN
1 The effects on heart rate and blood pressure after single and multiple dosing (1 month) of a long acting formulation of propranolol 160 mg daily, and conventional propranolol, 80 mg twice daily, or 160 mg daily were compared in 11 moderately hypertensive subjects previously shown to respond to propranolol. 2 After acute dosing all three treatments produced significant reduction in blood pressure. After multiple dosing all three treatments maintained significant reductions in lying, standing and exercise heart rate and blood pressure throughout the 24 h. At 24 h, after multiple dosing, the fall in resting and standing systolic BP was significantly greater with LA propranolol than with conventional propranolol 80 mg twice daily or conventional propranolol 160 mg once daily (P at least less than 0.05). 3 The plasma propranolol concentration time curve after LA propranolol showed slowed absorption, and the area under the curve was significantly lower than after conventional propranolol (acute dosing; LA propranolol 160 mg 560 mg ml-1 h, conventional propranolol 80 mg twice daily 1135 mg ml-1 h, conventional propranolol 160 mg daily 1414 mg ml-1 h).
Asunto(s)
Hipertensión/tratamiento farmacológico , Propranolol/administración & dosificación , Adulto , Presión Sanguínea/efectos de los fármacos , Preparaciones de Acción Retardada , Femenino , Humanos , Cinética , Masculino , Persona de Mediana Edad , Propranolol/sangre , Propranolol/metabolismo , Propranolol/uso terapéutico , Pulso Arterial/efectos de los fármacosRESUMEN
Fifteen patients with rheumatoid arthritis received indomethacin in three treatment schedules; indomethacin retard 75 mg twice daily; indomethacin capsules 50 mg three times daily; and indomethacin 100 mg suppository at night with 50 mg by mouth each morning. The study was a double-blind, double-dummy one with each treatment being given for 2 weeks after a washout period of 3 days. After the washout period, and at the end of each 2 week active treatment period, blood samples were taken during a dosage interval for assay of indomethacin concentrations in plasma. Clinical assessments were also performed. All three treatment period produced significant clinical improvements in the assessments compared with the placebo washout period. However, no differences were seen between the treatments. Side effects occurred with equal frequency in all three periods, and the anticipated reduction in central nervous system side effects during the indomethacin retard period was not seen. Plasma concentrations of indomethacin were significantly higher during indomethacin retard therapy with a peak concentration of 2500 +/- 25 ng ml-1 during indomethacin retard therapy (mean +/- s.d.) and 1900 +/- 200 ng ml during conventional oral therapy. Indomethacin retard is as effective as the other formulations of indomethacin but appears to offer no significant advantages.
Asunto(s)
Indometacina/administración & dosificación , Anciano , Artritis Reumatoide/tratamiento farmacológico , Preparaciones de Acción Retardada , Femenino , Humanos , Indometacina/metabolismo , Cinética , Masculino , Persona de Mediana EdadRESUMEN
In 6 patients anticoagulated with warfarin, nicoumalone, or phenindione the addition of cimetidine prolonged the prothrombin-time (PT) by a mean of 12.6 s (range 5--23 s). In 7 volunteers taking daily subtherapeutic doses of warfarin the addition of cimetidine increased the PT from 19.4 to 22.9 s and the plasma-warfarin concentration from 0.96 to 1.76 microgram/ml. Cimetidine reduced the single-dose clearance of warfarin and antipyrine. The basis of the interaction between cimetidine and oral anticoagulants is probably inhibition of drug metabolism. Care should be exercised in concomitant therapy.